Drug Search Results
More Filters [+]

Cixutumumab

Alternative Names: cixutumumab, imc-a12
Latest Update: 2024-04-02
Latest Update Note: Clinical Trial Update

Product Description

A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cixutumumab)

Mechanisms of Action: IGF Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cixutumumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Primitive Neuroectodermal Tumors|Soft Tissue Cancer|Synovial Sarcoma|Osteosarcoma|Pancreatic Cancer|Peritoneal Cancer|Neuroblastoma|Embryonal Rhabdomyosarcoma|Liver Cancer|Adrenocortical Carcinoma|Kidney Cancer|Peripheral Neuroectodermal Tumors, Primitive|Hepatocellular Carcinoma|Mesothelioma|Hepatoblastoma|Embryonal Carcinoma|Wilms Tumor|Retinoblastoma|Sarcoma, Ewing|Prostate Cancer|Small Cell Lung Cancer|Rhabdomyosarcoma|Leiomyosarcoma|Adenocarcinoma|Non-Small-Cell Lung Cancer|Breast Cancer|Hemangiosarcoma|Alveolar Soft Part Sarcoma|Alveolar Rhabdomyosarcoma|Squamous Cell Carcinoma|Uveal Melanoma|Neurofibrosarcoma|Liposarcoma|Neuroendocrine Carcinoma|Gliosarcoma|Neuroendocrine Tumors|Head and Neck Cancer|Gastrointestinal Cancer|Esophageal Cancer|Bronchiolo-Alveolar Adenocarcinoma|Male Breast Cancer|Colorectal Cancer|Large Cell Carcinoma

Phase 1: Oncology Solid Tumor Unspecified|Anemia|Hypertension|Hepatocellular Carcinoma|Islet Cell Carcinoma|Peripheral Neuroectodermal Tumors, Primitive|Neutropenia|Thrombocytopenia|Hyperglycemia|Malignant Carcinoid Syndrome|Primitive Neuroectodermal Tumors|Neuroendocrine Tumors|Sarcoma, Ewing|Paraganglioma|Pancreatic Cancer|Gastrointestinal Cancer|Neuroendocrine Carcinoma|Glioma|Insulinoma|Pinealoma|Carcinoma, Merkel Cell|Medullary Carcinoma|Carcinoid Tumor|Glucagonoma|Gastrinoma|Carotid Body Tumor|Somatostatinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCI-2011-03039

P2

Completed

Head and Neck Cancer|Squamous Cell Carcinoma

2018-08-15

BATTLE-FL

P2

Completed

Non-Small-Cell Lung Cancer

2017-08-15

NCI-2011-01917

P2

Completed

Small Cell Lung Cancer

2016-11-15

10-C-0146

P2

Completed

Mesothelioma|Peritoneal Cancer

2016-08-13

Recent News Events